Why Is AMGN Up 8.15% Today?
Amgen delivered a strong Q4 earnings report that has investors excited about its future prospects, particularly in the obesity and pharmaceutical markets. The company beat expectations with 9% revenue growth and issued robust guidance for 2026, sparking significant investor confidence.
- Q4 earnings significantly exceeded market expectations, with the company reporting 9% revenue growth and a double-digit volume boost. The strong performance has positioned Amgen in an attractive buy zone for investors.
- Analysts are showing increased interest in Amgen's strategic focus on obesity studies and potential market opportunities. The company appears to be sharpening its approach to this potentially lucrative therapeutic area.
- Potential regulatory challenges remain for some products, including emerging tensions around Tavneos, which could impact future performance. The company will need to carefully navigate these regulatory landscapes.
- The broader pharmaceutical market is closely watching Amgen's product portfolio expansion and pipeline progress. The Q4 earnings call highlighted the company's strategic initiatives and future growth potential.
- Potential loss of exclusivity (LOE) for certain drugs remains a concern that could impact long-term revenue streams. Amgen will need to continue innovating to mitigate these challenges.
- The company's strong 2026 outlook and continued investment in promising therapeutic areas, especially obesity treatments, present significant growth opportunities. Amgen's strategic positioning looks increasingly promising.
Bottom line for investors: Amgen demonstrates robust financial performance and strategic positioning in the pharmaceutical market. Investors should continue monitoring the company's progress in obesity studies, pipeline development, and ability to mitigate potential regulatory and exclusivity challenges.
Key Statistics
Market Cap
$170.91B
P/E Ratio
24.38
Dividend Yield
0.03%
Volume
5,899,169
Avg Volume
2,779,716
52-Week High
$346.38
52-Week Low
$253.30
About Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Analyst Ratings
View All →
Avg Price Target
$368.50
(+0.6% upside)
| Date | Firm | Rating |
|---|---|---|
| Dec 3, 2025 | BMO Capital | |
| Nov 14, 2025 | Piper Sandler | |
| Nov 6, 2025 | Cantor Fitzgerald | |
| Nov 5, 2025 | Wells Fargo | |
| Nov 5, 2025 | Morgan Stanley |
